Recent advances in the mechanisms and treatment of immune thrombocytopenia

Drew Provan, John W Semple

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review


Primary immune thrombocytopenia is an autoimmune disease associated with a reduced peripheral blood platelet count. The phenotype is variable with some patients suffering no bleeding whilst others have severe bleeding which may be fatal. Variability in clinical behaviour and treatment responses reflects its complex underlying pathophysiology. Historically the management has relied heavily on immune suppression. Recent studies have shown that the older empirical immune suppressants fail to alter the natural history of the disease and are associated with a poor quality of life for patients. Newer treatments, such as the thrombopoietin receptor agonists, have transformed ITP care. They have high efficacy, are well tolerated and improve patients' quality of life. A greater understanding of the underlying pathophysiology of this disorder has helped develop a number of new targeted therapies. These include inhibitors of the neonatal Fc receptor inhibitors, Bruton tyrosine kinase and complement pathway. Here we discuss the mechanisms underlying ITP and the new approach to ITP care.

Sidor (från-till)1-10
StatusPublished - 2022

Bibliografisk information

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Ämnesklassifikation (UKÄ)

  • Hematologi


Utforska forskningsämnen för ”Recent advances in the mechanisms and treatment of immune thrombocytopenia”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här